NKTR

Business Context and Reporting Period

Company: Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.)
Reporting Period: Fiscal year ended December 31, 2002
Business Model: A drug delivery technology company focused on three proprietary platforms: Nektar Molecule Engineering (advanced PEGylation), Nektar Particle Engineering (supercritical fluids and pulmonary particle technology), and Nektar Delivery Solutions (pulmonary administration systems). The company generates revenue primarily through collaborative research agreements, milestone payments, and manufacturing of PEG reagents for partners, rather than direct product sales.

Key Financial Metrics

Profitability: The company reported a net loss of $107.5 million for 2002, a significant improvement from the $250.0 million loss in 2001. This improvement was largely driven by the adoption of new accounting standards (SFAS 142) which eliminated goodwill amortization expenses ($22.5 million in 2001) and the absence of large in-process research and development (IPR&D) charges that occurred in 2001 due to acquisitions.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 22% to $94.8 million, driven by increased activities under the collaborative agreement with Pfizer (which accounted for 59% of 2002 revenue) and product sales from the Nektar AL subsidiary (19% of revenue).
• Expense Reduction: Operating expenses decreased significantly compared to 2001 due to the cessation of goodwill amortization and the absence of $146.3 million in IPR&D charges related to the 2001 acquisitions of Shearwater and Bradford Particle Design.
• Workforce Reduction: In December 2002, the company reduced its workforce by 73 employees (approximately 10% of the base), recording a $2.6 million charge. This is expected to reduce 2003 operating expenses by approximately $8.0 million.
• Capital Structure: In January 2002, the company entered a strategic alliance with Enzon Pharmaceuticals, receiving a $40.0 million investment in Series B Convertible Preferred Stock.

Guidance, Outlook, and Risks

Outlook: Management forecasts continued substantial operating losses over the next few years as the company expands R&D and commercial readiness. The company expects to have sufficient cash to meet net operating expense requirements for at least the next two years. However, it anticipates a decrease in internally funded research spending in the next 3-5 years as it shifts infrastructure costs to cost of goods sold and partners proprietary projects.

Key Risks and Contingencies:

• Exubera (Inhaled Insulin) Delay: Pfizer, the partner for the company's most significant program (Exubera), announced in January 2003 that it would not file a New Drug Application (NDA) in 2003 due to the need for additional long-term safety data regarding pulmonary function. A delay or failure to obtain approval would significantly harm the company's financial position, as Pfizer represented 59% of 2002 revenue.
• Liquidity and Debt: The company has approximately $299.2 million in long-term convertible subordinated notes and debentures maturing in 2006 and 2007. It is not currently generating positive cash flow from operations and may need to raise additional capital to meet these obligations.
• Legal Proceedings: A lawsuit filed in August 2002 by David F. Kachensky seeks approximately $15 million in damages related to an alleged breach of agreement prior to the acquisition of Shearwater. The company intends to vigorously defend the claim.
• Regulatory Approval: Success depends on partners obtaining regulatory approval for products using Nektar's technologies. Many products are in early clinical stages, and there is no assurance of commercial viability.

Investor Verification Checklist

• Exubera Status: Verify the latest timeline for Pfizer's NDA filing for Exubera and the results of the additional long-term pulmonary safety studies.
• Debt Maturity: Confirm the company's strategy for refinancing or repaying the $299.2 million in convertible notes maturing in 2006 and 2007, given the current lack of positive operating cash flow.
• Revenue Concentration: Assess the risk associated with Pfizer representing 59% of total revenue and the potential impact of any changes to that collaboration.
• Legal Exposure: Monitor the status of the $15 million lawsuit filed by David F. Kachensky regarding the Shearwater acquisition.
• Product Pipeline: Review the progress of other key pipeline products (e.g., Macugen, PEGASYS, Somavert) to determine if they can offset potential revenue declines from the Exubera delay.